New Discorhabdin B Dimers with Anticancer Activity from the Antarctic Deep-Sea Sponge Latrunculia biformis by Li, Fengjie et al.
  
Mar. Drugs 2020, 18, 107; doi:10.3390/md18020107 www.mdpi.com/journal/marinedrugs 
Article 
New Discorhabdin B Dimers with Anticancer 
Activity from the Antarctic Deep-Sea Sponge 
Latrunculia biformis  
Fengjie Li 1, Dorte Janussen 2 and Deniz Tasdemir 1,3,* 
1 GEOMAR Centre for Marine Biotechnology (GEOMAR-Biotech), Research Unit Marine Natural Products 
Chemistry, GEOMAR Helmholtz Centre for Ocean Research Kiel, Am Kiel-Kanal 44, Kiel 24106, Germany; 
fli@geomar.de 
2 Senckenberg Research Institute and Natural History Museum, Senckenberganlage 25, Frankfurt D-60325, 
Germany; dorte.janussen@senckenberg.de 
3 Faculty of Mathematics and Natural Sciences, Kiel University, Christian-Albrechts-Platz 4, Kiel 24118, 
Germany 
* Correspondence: dtasdemir@geomar.de; Tel.: +49-431-600-4430 
Received: 28 January 2020; Accepted: 7 February 2020; Published: 11 February 2020 
Abstract: Latrunculia sponges represent a rich source of discorhabdin-type pyrroloiminoquinone 
alkaloids, a few of which comprise a dimeric structure. The anticancer-activity-guided isolation of 
the n-hexane subextract of the Antarctic deep-sea sponge Latrunculia biformis yielded the known 
compound (−)-(1R,2R,6R,8S,6'S)-discorhabdin B dimer (1) and two new derivatives, (−)-
(1S,2R,6R,8S,6'S)-discorhabdin B dimer (2) and (−)-(1R,2R,6R,8S,6'S)-16',17'-dehydrodiscorhabdin B 
dimer (3). The chemical structures of compounds 1–3 were elucidated by means of HR-ESIMS, 
NMR, [α] D , ECD spectroscopy, and a comparison with the previously reported discorhabdin 
analogs. Compounds 1 and 2 showed significant in vitro anticancer activity against the human colon 
cancer cell line (HCT-116), with IC50 values of 0.16 and 2.01 µM, respectively. Compared to 
monomeric discorhabdins, dimeric discorhabdins are very rare in Nature. This study adds two new 
discorhabdin dimers (2 and 3) to this small pyrroloiminoquinone subfamily. This is also the first 
report of compound 1 as a natural product and the first assessment of its in vitro anticancer activity.  
Keywords: Latrunculia biformis; discorhabdin B dimer; deep-sea sponge; Antarctica; anticancer 
activity; ECD spectroscopy  
 
1. Introduction 
Latrunculia is the largest genus of the marine sponge family Latrunculiidae Topsent (Class 
Demospongiae Sollas, Order Poecilosclerida Topsent) [1,2]. The members of this genus are 
predominately distributed in cold-water regions of the Southern Hemisphere [3,4]. Continuing 
reports of pyrroloiminoquinone-type alkaloids with strong anticancer activity from Latrunculia 
sponges have been the main driving force for in-depth chemical analyses of this genus [5–12]. So far, 
Latrunculia sponges represent one of the major reservoirs of pyrroloiminoquinone-type alkaloids. 
More than 40 pyrroloiminoquinone alkaloids belonging to the subclasses tsitsikammamines, 
makaluvamines, and discorhabdins have been reported from this genus, the discorhabdins being the 
largest and the most diverse [5,8,13,14]. Discorhabdins are a unique class of nitrogenous pigments 
possessing a characteristic tetracyclic pyrido[2,3-h]pyrrolo[4,3,2-de]quinoline core bound to a 
cyclohexanone substituent at the spiro center C-6 [5]. Discorhabdins lend themselves for various 
types of substitutions, such as bromination at C-2 or C-4, which is common in discorhabdins. Some 
discorhabdins bear a heptacyclic backbone through further intramolecular cyclization via a bond 
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formation between C-2 and N-18 and/or possess a thioether bridge between C-5 and C-8 [6,7,15]. The 
broad-spectrum anticancer activity of discorhabdins against various cancer cell lines, e.g., HCT-116 
(human colon cancer cell line), P388 (murine leukemia cell line), and KB (human oral cancer cell line) 
have been reported [5,16]. Compared to monomeric discorhabdins, dimeric discorhabdins are highly 
uncommon. So far, only five natural discorhabdin dimers ((+)-discorhabdin W, (−)-discorhabdin W, 
(+)-16a,17a-dehydrodiscorhabdin W, (−)-16a,17a-dehydrodiscorhabdin W, and (−)-28,29-
dihydrodiscorhabdin B dimer) that are linked to each other with a sulfide or disulfide bond have 
been reported and all derive from Latrunculia sp. collected from New Zealand or Australia [11,17,18]. 
In addition, the discorhabdin B dimer has been reported as an artifact that formed after the storage 
of discorhabdin B [19]. Notably, the discorhabdin dimers exhibit promising anticancer activities in 
the same magnitude as the monomeric discorhabdins [11,17]. 
In a recent study, we reported new discorhabdin monomers from the MeOH subextract of the 
Antarctic deep-sea sponge L. biformis [14]. In the continuation of the chemical investigation of this 
sponge, we have now focused on its n-hexane-soluble portion. Guided by in vitro anticancer activity 
against the human colon cancer cell line (HCT-116), we herein report three dimeric discorhabdins, 
the known compound (−)-(1R,2R,6R,8S,6'S)-discorhabdin B dimer (1) and two of its new derivatives, 
(−)-(1S,2R,6R,8S,6'S)-discorhabdin B dimer (2) and (−)-(1R,2R,6R,8S,6'S)-16',17'-dehydrodiscorhabdin 
B dimer (3) from the n-hexane subextract of L. biformis. This study outlines the bioactivity-guided 
isolation and structure elucidation of compounds 1–3, and in vitro anticancer activity determination 
of 1 and 2.  
2. Results 
2.1. Purification and Structure Elucidation 
As described previously [14], the sponge material was desalted with water, and extracted by 
methanol and dichloromethane, respectively. The combined organic extract was partitioned between 
MeOH and n-hexane. The C18 SPE fractionation of the n-hexane subextract yielded nine subfractions 
(H1-H9). Repeated RP-HPLC of the active subfractions H4 and H5 afforded three minor compounds, 
1–3 (Figure 1). 
 
Figure 1. Chemical structures of compounds 1–3. 
The structure of compound 1 was identified by comparison of its HRMS and 1D NMR data 
( Table 1;  Table 2) with those reported for discorhabdin B dimer [19]. Furthermore, we revised the 
chemical shifts of several quaternary carbon atoms, C-15, C-21, C-15’, and C-21’, on the basis of full 
2D NMR data analysis (Table 2). The HMBC correlations between H-16/C-21 and H-17/C-15 
(Supplementary Figure S3), led to the assignment of the 13C signals at δC 119.4 and δC 122.8 to C-15 
and C-21, respectively, which were ascribed vice versa in the literature [19]. The chemical shifts of C-
15’ and C-21’ were also revised in the same fashion. The [α]20D value of compound 1 (−144, c 0.01 MeOH) 
had the same sign and similar magnitude as the known compound (−)-(1R,2R,6R,8S,27S)-
discorhabdin B dimer (−120, c 0.05 MeOH) [19]. Hence, compound 1 was characterized as the (−)-
(1R,2R,6R,8S,6'S)-discorhabdin B dimer.  
N
H
N+
N
H
S
O
O
N
H
NH
Br
O
O
S
H
N
1
3
5
7
1012
14
16
19 2021
1'
3'
5'
7'
10' 12'
14'
16'
19'20' 21'
N
H
N+
N
H
S
O
O
N
H
NH
Br
O
O
S
H
N
N
H
N+
N
H
S
O
O
N
H
NH
Br
O
O
S
H
N
1 2 3
Mar. Drugs 2020, 18, 107 3 of 11 
 
Table 1. 1H NMR (600 MHz) data of compounds 1–3 in CD3OD (TFA salts, δ in ppm). 
Position 
1 2 3 
δH, Mult. (J in Hz) δH, Mult. (J in Hz) δH, Mult. (J in Hz) 
1 4.72 d (3.1) 5.03 d (2.6) 4.53 d (3.1) 
2 4.45 d (3.1) 4.43 d (2.6) 4.45 d (3.1) 
4 6.17 s 6.27 s 6.04 s 
7α 2.71 dd (1.3, 12.0) 2.76 dd (1.5, 11.7) 2.31 dd (1.5, 12.0) 
7β 2.91 dd (3.7, 12.0) 2.95 dd (3.6, 11.7) 2.38 dd (3.7, 12.0) 
8 5.62 dd (1.3, 3.7) 5.58 dd (1.5, 3.6) 5.30 dd (1.5, 3.7) 
14 7.15 s 7.09 s 7.13 s 
16 
3.24 m 
3.03 m 
3.24 m 
3.10 ddd (2.6, 6.5, 16.3) 3.07 ddd (2.7, 6.8, 16.3) 
17 
4.13 ddd (2.6, 7.4, 13.9) 
3.91 m 
4.11 ddd (2.7, 7.3, 14.2) 
3.91 m 3.89 m 
1’ 7.89 s 7.87 (s) 7.91 s 
4’ 6.66 s 6.72 s 6.48 s 
7’ 4.79 d (7.5) 4.82 d (7.5) 4.21 d (7.5) 
8’ 6.57 d (7.5) 6.58 d (7.5) 6.60 d (7.5) 
14’ 7.25 s 7.23 s 8.15 s 
16’ 2.98 m 2.97 m 7.64 d (6.0) 
17’ 3.91 m 3.91 m 8.19 d (6.0) 
TFA: Trifluoroacetic acid 
Compound 2 was purified as a greenish TFA salt. The HR-ESIMS spectrum of 2 showed the 
quasi-molecular ions at m/z 747.0487/749.0476 [M]+ (Supplementary Figure S12) in a ratio of 
approximately 1:1, indicating the presence of one bromine atom and hence generating the same 
molecular formula C36H24BrN6O4S2 as 1. A comparison of the 1H and 13C NMR spectra of 2 with those 
of 1 (Tables 1 and 2) revealed high similarity between these two compounds, indicating that 2 is a 
dimeric discorhabdin alkaloid. A detailed analysis of the 1D and 2D NMR data of 2 suggested the 
presence of five sp3 methylenes, three sp3 methenes, seven sp2 methenes, and 21 quaternary carbon 
signals belonging to two sp3 and 19 sp2 carbon atoms (Tables 1 and 2). To facilitate the structure 
elucidation and interpretation of the NMR data of 2, we assigned the letters A and B for each 
discorhabdin monomer (Figure 2). Characteristic 1H NMR resonances attributed to component A for 
a pyrroloiminoquinone moiety in the spectrum of 2 included those appeared at δH 7.09 (H-14), δH 5.58 
(H-8), δH 3.91 (H2-17), δH 3.03 (H2-16), δH 2.95, and 2.76 (H2-7) (Table 1) [9–11,14]. The tetracyclic 
pyrroloiminoquinone core structure of component A was readily ascertained by the 2D COSY and 
HMBC correlations shown in Figure 2. In detail, the COSY cross-peak between H2-16 and H2-17 
together with the observed HMBC correlations between H2-16/C-15, H2-17/C-15, H2-17/C-19, H-14/C-
11, H-14/C-12, and H-14/C-21 established the tricyclic pyrrolo[4,3,2-de] quinoline moiety (Figure 2). 
The tetrahydropyridine ring could then be connected to the tricyclic system based on the COSY 
correlation between H2-7 and H-8 and the HMBC correlations between H2-7/C-20 and H-8/C-10, 
which establishes the tetracyclic pyrroloiminoquinone core structure of A (Figure 2). The 2D COSY 
cross-peak between H-1 and H-2, and the HMBC correlations between H-1/C-5, H-1/C-6, H-1/C-20, 
H-2/C-1, H-2/C-3, H-2/C-6, H-4/C-2, and H-4/C-6 supported the presence of a cyclohexanone 
substitution at the spiro center, C-6. The down-field shifted resonances of C-5 (δC 174.4), C-8 (δC 62.8), 
and H-8 (δH 5.58) indicated the presence of a sulfide bridge between C-5 and C-8 [9–11,14]. This 
assumption was further supported by a diagnostic HMBC correlation between H-8 and C-5 (Figure 
2). HMBC correlations between H-2/C-17 and H-2/C-19 revealed a further intramolecular ring closure 
via a bond formation between C-2 and N-18 (Figure 2). The multiplicity and the down-field chemical 
shift of H-1 (δH 5.03, d, J = 2.6 Hz) and H-2 (δH 4.43, d, J = 2.6 Hz) indicated an electronegative 
substitution at C-1. Thus, A was elucidated as a C1-substituted discorhabdin L-type alkaloid.  
The pyrroloiminoquinone moiety in component B was established in a similar fashion. The 1H 
NMR resonances at δH 7.23 (H-14’), δH 3.91 (H2-17’), and δH 2.97 (H2-16’) signified the existence of a 
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pyrroloiminoquinone moiety in unit B (Table 1), which was further ascertained by the observed 
COSY and HMBC correlations shown in Figure 2. The COSY correlation between H-7’ (δH 4.82, d, J = 
7.5 Hz) and H-8’ (δH 6.58, d, J = 7.5 Hz) and the observed HMBC correlations between H-7’/C-6’, H-
7’/C-8’, H-7’/C-20’ and H-8’/C-6’, H-8’/C-7’, H-8’/C-10’ supported the ∆7’(8') unsaturation (Figure 2). 
Further HMBC correlations shown in Figure 2, namely between H-1’/C-2’, H-1’/C-3’, H-1’/C-5’, H-
1’/C-6’, H-1’/C-20’ and H-4’/C-2’, H-4’/C-5’, H-4’/C-6’ indicated a cyclohexanone moiety at C-6’. 
Based on the similarity of the chemical shift of C-2' (δC 124.4) to that of discorhabdin W, which 
contains a bromine atom at C-2' (δC 125.1) [9], as well as the observation of an HMBC correlation 
between H-4' and C-2', the bromine atom was assigned to C-2'. The down-field shift of C-5' (δC 164.7) 
and the HMBC correlation between H-1'/C-5' completed the full structure elucidation of B and 
proved the presence of a thioether bridge between C-1 and C-5’ (Figure 2). Hence, the planar dimeric 
structure of 2 was confirmed. 
Table 2. 13C NMR (150 MHz) data of compounds 1–3 in CD3OD (TFA salts, δ in ppm). 
Position 
1 2 3 
δC a δC a δC  
1 46.0 (CH) 44.9 (CH) 45.8 (CH) 
2 65.6 (CH) 68.0 (CH) 66.1 (CH) 
3 182.3 (C) 183.7 (C) 182.3 (C) 
4 114.4 (CH) 114.8 (CH) 114.4 (CH) 
5 171.0 (C) 174.4 (C) 171.7 (C) 
6 46.6 (C) 48.3 (C) 47.0 (C) 
7 38.8 (CH2) 39.2 (CH2) 38.4 (CH2) 
8 63.8 (CH) 62.8 (CH) 63.6 (CH) 
10 148.6 (C) 150.4 (C) 148.4 (C) 
11 167.0 (C) 167.0 (C) / 
12 125.4 (C) 125.8 (C) 125.4 (C) 
14 127.5 (CH) 127.5 (CH) 127.4 (CH) 
15 119.4 (C) 119.5 (C) 119.4 (C) 
16 20.8 (CH2) 20.7 (CH2) 20.7 (CH2) 
17 52.9 (CH2) 52.9 (CH2) 52.9 (CH2) 
19 150.4 (C) 150.6 (C) 150.2 (C) 
20 101.1 (C) 98.6 (C) 101.2 (C) 
21 122.8 (C) 122.7 (C) 122.8 (C) 
1’ 150.5 (CH) 150.2 (CH) 156.0 (CH) 
2’ 124.3 (C) 124.4 (C) 120.0 (C) 
3’ 176.2 (C) 176.2 (C) 178.4 (C) 
4’ 122.3 (CH) 121.9 (CH) 118.7 (CH) 
5’ 163.2 (C) 164.7 (C) 171.4 (C) 
6’ 50.8 (C) 50.7 (C) 52.5 (C) 
7’ 115.1 (CH) 114.9 (CH) 103.9 (CH) 
8’ 126.9 (CH) 126.4 (CH) 128.8 (CH) 
10’ 146.8 (C) 147.2 (C) 142.3 (C) 
11’ 166.5 (C) 166.5 (C) / 
12’ 125.6 (C) 125.8 (C) 120.9 
14’ 127.5 (CH) 127.5 (CH) 129.7 (CH) 
15’ 120.9 (C) 121.2 (C) 126.3 (C) 
16’ 19.3 (CH2) 19.2 (CH2) 115.9 (CH) 
17’ 46.2 (CH2) 46.1 (CH2) 142.0 (CH) 
19’ 159.9 (C) 160.4 (C) 148.4 (C) 
20’ 95.8 (C) 96.1 (C) 108.0 (C) 
21’ 123.2 (C) 123.2 (C) 121.0 (C) 
a extracted from HSQC and HMBC spectra. TFA: Trifluoroacetic acid 
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Figure 2. Key COSY (bold lines) and HMBC (arrows) correlations observed for compound 2. The 
letters A and B indicate each discorhabdin monomer. 
The identification of the relative configuration of 2 was mainly based on its NOE data (Figure 3). 
Due to a further intramolecular ring closure formed by the sulfide bridge between C-5 and C-8, and 
the direct bond between C-2 and N-18, the unit A was configurationally restrained. This allows only 
one stable relative configuration at C-2, C-6, and C-8, implying that C-2/C-3, C-6/C-7, and C-8/S are 
syn-periplanar to each other (Figure 3A). The diastereotopic methylene resonances at δH 2.76 (dd, J = 
1.5, 11.7 Hz) and 2.95 (dd, J = 3.6, 11.7 Hz) were assigned to have α and β orientations, respectively, 
according to the long-range COSY correlation (Supplementary Figure S10) between H-4 (δH 6.27 ppm) 
and H-7α (δH 2.76 ppm). This correlation indicated a planar ‘W’ arrangement [20], which is very 
common for many heptacyclic discorhabdins, e.g., discorhabdin D, discorhabdin L, and 1-
acetyldiscorhabdin L [7,14,15]. The NOE correlation between H-1 and H-7β indicated the β-
orientation of H-1, which was further supported by the NOE cross-peaks between H-1/H-4’, H-1/H-
2, H-4’/H-7β, and H-4’/H-2 (Figure 3A). The relative configuration of the stereocenters in B (C-6’) was 
established by the NOE correlation between H-7' and H-7α (Figure 3A). Since the relative 
configuration of unit A was established, two molecular models (B1 and B2) that represented the two 
possible relative configurations at C-6’ were proposed (Figure 3B). Only B1 allows a NOESY 
correlation between H-7'/H-7α, confirming the same relative configuration of C-6’ as in 1. Thus, 
compound 2 was elucidated as an epimer of 1, with an opposite configuration at C-1.  
  
                                                                                          B1                                                    B2 
Figure 3. (A) Key NOE correlations drawn on a Chem3D optimized model of 2. (B) Two proposed 
molecular models (B1 and B2) of 2.  
The absolute configuration of 2 was established by ECD spectroscopy. The ECD spectra of 
discorhabdin-type alkaloids with a stereogenic spiro center at C-6 are characterized by a high-
amplitude Cotton effect (CE) in the 325–400 nm region, whereby positive and negative CEs in this 
region of the ECD spectra imply a β- and an α-orientation of C-5/C-6 bond, respectively, when the 
pyrroloiminoquinone backbone is drawn as unit A in Figure 1 [9–11,14]. Hence, the high-amplitude 
positive CE around 350 nm in the ECD spectrum of 2 signifies a β-oriented C-5/C-6 bond in unit A 
A 
B 
A B 
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(Figure 4). Considering the assigned relative configuration and the same sign of its optical rotation 
([α]20D −473, c 0.05, MeOH) as that of 1 ([α]
20
D −144, c 0.01 MeOH), 2 was established as a new compound, 
namely (−)-(1S,2R,6R,8S,6'S)-discorhabdin B dimer.  
 
Figure 4. Experimental ECD spectra (MeOH) of the TFA salts of (−)-2 (black) and (−)-3 (red). 
Compound 3 was purified as an orange TFA salt. Its molecular formula was deduced as 
C36H22BrN6O4S2 from the molecular ions (m/z 745.0328/747.0319 [M]+) observed in its HR-ESIMS 
spectrum (Supplementary Figure S19). This indicated the presence of 29 degrees of unsaturation. A 
comparison of the 1D NMR data of 3 with those of 1 revealed a high resemblance between the two 
molecules. The major difference was the replacement of the two methylene resonances, namely H2-
16’and H2-17’ with two olefinic protons in 3 (H-16’, δH 2.97 in 1 and δH 7.64 in 3; H-17’ δH 3.91 in 1 and 
δH 8.19 in 3), indicating that 3 is a new dehydro derivative of 1 ( Table 1;  Table 2). The 2D structure 
of 3 was further confirmed by an in-depth inspection of its 2D NMR data shown in Figure 5. A 1H-1H 
COSY correlation between H-16’ and H-17’, coupled with the HMBC correlations between H-16'/C-
14', H-17'/C-16', and H-17'/C-19', confirmed the position of the double bond at ∆16’(17’) (Figure 5). The 
carbonyl signals belonging to C-11 and C-11’ did not appear in the NMR spectra, which is a common 
case in many pyrroloiminoquinone alkaloids [11,12,14]. Our attempts to locate the two carbonyl 
carbons by using a high-resolution cryo NMR probe were unsuccessful, however, the structural 
homology was obvious based on the HRMS, 1D, and 2D NMR data and the comparison of the data 
with related compounds in the literature [18,19].  
 
Figure 5. Key COSY (in bold) and HMBC (arrows) correlations observed for compound 3. 
The relative configuration of 3 was established in the same fashion as 2. Based on its NOESY 
spectrum, C-2, C-6, and C-8 in A had the same relative configurations as in 1 and 2 (Figure 6A). NOE 
correlations between H-1/H-7α, H-1/H-4’, H-1/H-2, H-2/H-4’, and finally between H-4’/H-7α 
confirmed the α-orientation of H-1, which is the same in 1 (Figure 6A). For B, the relative 
configuration at C-6’ was established by the NOE correlation between H-17’ and H-7β (Figure 6A). 
Two molecular models (B1 and B2) representing two possible relative configurations at C-6’ were 
proposed, with only B1 allowing a spatial correlation (H-17’/H-7β). Hence, the relative configuration 
A 
B 
∆ε
 (M
-1
 c
m
-1
) 
λ (nm) 
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of 3 was established, as shown in Figure 6A. The high-amplitude positive Cotton effect around 375 
nm in the ECD spectrum of 3 indicates a β-oriented C-5/C-6 bond in A (Figure 4). Hence, the absolute 
configuration of 3 was identified as 1R,2R,6R,8S,6'S, which was further supported by its ECD 
spectrum (Figure 4). The specific rotation value of 3 ([α]20D −239, c 0.1 MeOH) confirmed its structure 
as a (−)-(1R,2R,6R,8S,6'S)-16’,17’-dehydrodiscorhabdin B dimer.  
  
                                                                                          B1                                                    B2 
Figure 6. (A) Key NOE correlations drawn on a Chem3D optimized model of 3. (B) Two proposed 
molecular models (B1 and B2) of 3. 
2.2. Bioactivity Evaluation  
Due to a supply issue, only compounds 1 and 2 were tested against the human colon cancer cell 
line (HCT-116) and the human keratinocyte cell line (HaCaT) (Table 3). Limited by its minute amount, 
compound 3 was not tested in any cell line. Both 1 and 2 showed promising anticancer activity against 
HCT-116 cells with IC50 values of 0.16 and 2.01 µM, respectively (Table 3). However, they also 
inhibited the growth of HaCaT cells with similar IC50 values (0.56 and 4.69 µM for 1 and 2, 
respectively, Table 3), indicating their general toxicity. 
Table 3. In vitro bioactivity and toxicity of compounds 1 and 2. 
 
IC50 values (μM) 
HCT-116 Cells HaCaT Cells 
Compound 1 a 0.16 0.56 
Compound 2 a 2.01 4.69 
Negative (solvent) control b - - 
Positive control c 22.1 35.1 
a All compounds were tested as TFA salts; b Solvent control: 0.5% DMSO; c Positive control: doxorubicin. 
3. Discussions 
In a previous study, we isolated six monomeric discorhabdins from the MeOH subextract of the 
Antarctic deep-sea sponge L. biformis [14]. In the present study, we were able to isolate three more 
lipophilic dimeric discorhabdin alkaloids from the n-hexane subextract of the same sponge and 
determine their chemical structures despite their very minor amounts. Compared to discorhabdin 
monomers, dimeric discorhabdins are relatively rare. Out of over 40 discorhabdin alkaloids that have 
been reported so far, only five represent a dimeric structure [9–11,17,18]. Notably, discorhabdin B 
dimer (1) has been reported as an artifact of discorhabdin B after a long-time storage and its 
bioactivity has never been studied [19]. This is the first isolation of 1 as a natural product on its own. 
This is also the first assessment of 1’s in vitro anticancer activity. We exclude the possibility that the 
discorhabdin B dimer (1) can be an artifact of the isolation procedure, as we were able to detect the 
compound in the crude sponge extract. 
The structural elucidation of discorhabdins is hampered by their highly strained backbone, 
commonly found heteroatoms (N, O, S) and halogenation (e.g., Br), and a high degree of unsaturation. 
This explains the limited numbers of hydrogen atoms in the discorhabdin structure. In the case of 
dimeric discorhabdins, the overlapping resonances from two similar discorhabdin units make the 
A B 
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structural elucidation even more difficult. In the present study, structures of compounds 1–3 were 
unambiguously elucidated by an in-depth analysis of their spectroscopic data (HR-ESIMS, NMR, [α]D) 
and a comparison with the previously reported discorhabdins. Compound 2 was elucidated as a C-1 
epimer of the known compound 1. To our knowledge, this the first report of C-1 epimeric 
discorhabdins. Compound 3 was characterized as the dehydro derivative of 1, with the only 
difference contributed by the ∆16’(17’) unsaturation in unit B. With the exception of this difference, the 
2D structure of unit A remained the same for both compounds 1 and 3. The configuration of the 
stereogenic centers within 2 and 3 were secured by their NOESY and ECD spectroscopy data. The 
ECD spectroscopy was first employed in the structural elucidation of discorhabdins by Grkovic et al. 
in 2008 [9]. Since then, this technique has become particularly attractive and useful for confirming the 
absolute configuration of discorhabdins because of their conformationally rigid structures, strong UV 
absorption and circular dichroism properties [10,11,13,21]. So far, ECD spectroscopy is also one of the 
most effective techniques to secure the absolute configurations of discorhabdins-type alkaloids with 
a large number of stereogenic centers.  
Discorhabdin-type alkaloids are characterized by their wide spectrum of in vitro anticancer 
activities [5,16]. Notably, the anticancer potency of the dimeric discorhabdins is similar to the 
monomeric discorhabdin with IC50 values at a submicromolar level. For example, both enantiomeric 
pairs of discorhabdins W and 16a,17a-dehydrodiscorhabdin W exhibit very strong inhibition towards 
the P388 murine leukemia cell line with IC50 values ranging from 0.084 to 0.45 µM [9–11,17]. More 
recently, the 28,29-dihydro discorhabdin B dimer with promising activity against the HCT-116 cell 
line was reported as a novel inhibitor of HIF-1α/p300 protein–protein interactions [18]. In the current 
study, both compound 1 and its new epimer 2 were found to exhibit anticancer potency toward HCT-
116 with IC50 values of 0.16 and 2.01 µM, respectively. The fact that compound 1 displays 
approximately 13 times lower IC50 value than 2 against the HCT-116 cells may indicate that R 
stereochemistry at C-1 is favored for anticancer activity. In comparison to its monomeric unit (−)-
discorhabdin L (IC50 = 0.94 µM against HCT-116) [14], the potency of compound 1 is almost six times 
higher. However, when tested against the non-cancerous human keratinocyte cell line HaCaT, both 
compounds 1 and 2 show toxicity (Table 3), suggesting their low selectivity. Further isolation from 
natural resources coupled with the chemical synthesis of monomeric and dimeric discorhabdin 
derivatives may shed light on their structure–anticancer activity relationship and the reduction of 
their toxicity.  
4. Materials and Methods  
4.1. General Procedures  
The specific rotation of compounds 1–3 were measured on a Jasco P-2000 polarimeter (Jasco, 
Pfungstadt, Germany). The FT-IR spectra were recorded using a PerkinElmer Spectrum Two FT-IR 
spectrometer (PerkinElmer, Boston, MA, USA). The ECD spectra were run in MeOH on a J-810 CD 
spectrometer (Jasco, Pfungstadt, Germany). The NMR spectra were obtained on a Bruker AV 600 
spectrometer (600 and 150 MHz for 1H and 13C NMR, respectively, Bruker®, Billerica, MA, USA) 
equipped with 5.0 mm Shigemi tube (SHIGEMI, Co., LTD., Tokyo, Japan). The residual solvent 
signals were used as internal references: δH 3.31/δC 49.0 ppm (MeOD), and δH 2.50/δC 39.51 ppm 
(DMSO-d6). 4-Dimethyl-4-silapentane-1-sulfonic acid (DSS) served as the internal standard. HR-
ESIMS was recorded on a micrOTOF II-High-performance TOF-MS system (Bruker®, Billerica, MA, 
USA) equipped with an electrospray ionization source. Solid-phase extraction (SPE) was performed 
on the Chromabond SPE C18 column cartridges (6 mL/2000 mg, Macherey-Nagel, Duren, Germany). 
HPLC separations were performed on a VWR Hitachi Chromaster system (VWR International, 
Allison Park, PA, USA) consisting of a 5430 diode array detector (VWR International, Allison Park, 
PA, USA), a 5310 column oven, a 5260 autosampler, and a 5110 pump combined in parallel with a 
VWR Evaporative Light Scattering Detector (ELSD 90, VWR International, Allison Park, PA, USA). 
The eluents used for HPLC separations were H2O (A) and MeCN (B). Routine HPLC separations were 
performed on an analytical synergi column (250 × 4.6 mm, Phenomenex, Torrance, CA, USA) and an 
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analytical C6-Phenyl column (250 × 4.6 mm, Phenomenex, Torrance, CA, USA). The organic solvents 
used for HPLC isolation were HPLC grade (ITW Reagents, Darmstadt, Germany). The water used 
was MilliQ-water produced by Arium® Water Purification Systems (Sartorius, Germany). 
4.2. Sponge Material, Extraction, and Isolation 
The details of the collection and extraction of the sponge material have been reported previously 
[14]. Lyophilization and extraction of the sponge material followed by a liquid-liquid partition of the 
crude extract between MeOH and n-hexane yielded the polar MeOH and nonpolar n-hexane 
subextracts [14]. The n-hexane subextract (H, 120 mg) was eluted with a step gradient MeOH/H2O 
mixture (0% to 100%) on a Chromabond C18 SPE cartridge to afford 9 subfractions (H1–H9). The 
active subfractions H4 (14.9 mg) and H5 (22.0 mg) were further fractionated individually on a 
Chromabond C18 SPE cartridge eluted with a MeOH/H2O (0.1% TFA, from 60% to 100%) mixture to 
furnish further subfractions (H4.1 to H4.5; H5.1 to H5.5). The RP-HPLC chromatography of H4.1 (2.1 
mg) equipped with an analytical synergi column (gradient of H2O/MeCN from 75:25 to 70:30 in 10 
min; 70:30, 10–15 min, with 0.1% TFA, flow 1.0 mL/min) yielded compound 2 (0.2 mg, tR 10.8 min). 
The RP-HPLC chromatography of H4.3 (3.0 mg) on the same column (gradient of H2O/MeCN from 
74:26 to 69:31 in 10 min; 69:31, 10–17 min, with 0.1% TFA, flow 1.0 mL/min) afforded compound 1 
(0.3 mg, tR 12.2 min). The RP-HPLC chromatography of H5.2 (6.5 mg) on an analytical C6-Phenyl 
column (gradient of H2O/MeOH from 56:44 to 41:59 in 24 min, with 0.1% TFA, flow 1.0 mL/min) gave 
compound 3 in a pure state (0.1 mg, tR 14.8 min). 
(−)-(1R,2R,6R,8S,6'S)-Discorhabdin B dimer (1): green film; [α] 20D  = −144 (c 0.01, MeOH); 1H NMR 
(CD3OD, 600 MHz) and 13C NMR (CD3OD, 150 MHz, extracted from HSQC and HMBC spectra)  
Table 1;  Table 2; HR-ESIMS m/z [M]+ 747.0487 (calcd. for C36H24BrN6O4S2 747.0483).  
(−)-(1S,2R,6R,8S,6'S)-Discorhabdin B dimer (2): green film; [α]20D = −473 (c 0.05, MeOH); IR (film) vmax 
2916, 2848, 1675, 1620, 1561, 1524, 1203, 1132 cm−1; 1H NMR (CD3OD, 600 MHz) and 13C NMR (CD3OD, 
150 MHz, extracted from HSQC and HMBC spectra)  Table 1;  Table 2; HR-ESIMS m/z [M]+ 747.0487 
(calcd. for C36H24BrN6O4S2 747.0483). 
(−)-(1R,2R,6R,8S,6'S)-16',17'-Dehydrodiscorhabdin B dimer (3): orange film; [α]20D = −239 (c 0.1, MeOH); 
IR (film) vmax 2925, 2851, 1678, 1639, 1557, 1527, 1472, 1206 cm−1; 1H NMR (CD3OD, 600 MHz) and 13C 
NMR (CD3OD, 150 MHz)  Table 1;  Table 2; HR-ESIMS m/z [M]+ 745.0328 (calcd. for C36H22BrN6O4S2 
745.0327). 
4.3. Anticancer and Cytotoxicity Assays 
The human colon cancer cell line HCT-116 and the human keratinocyte cell line HaCaT were 
used for assessing anticancer activity (test concentration 100 µg/mL). Cells were supplemented at 37 
°C and 5% CO2 in RPMI (Roswell Park memorial institute) 1640 medium (Life Technologies, 
Darmstadt, Germany) with 10% fetal bovine serum, 100 U/mL penicillin, and 100 mg/mL 
streptomycin. A stock solution of 20 mg/mL in DMSO was prepared for each test sample. After a 24 
h incubation in 96 well plates, the medium in the cells was replaced by 100 µL fresh medium 
containing the test samples and cells were incubated for another 24 h at 37 °C. Doxorubicin was used 
as positive control, while 0.5% DMSO and the growth media served as negative controls. All samples 
were prepared in duplicates. The assay was performed according to the manufacturer’s instructions 
(Promega). Cells were incubated for 2h at 37°C, and fluorescence at an excitation wavelength of 560 
nm and emission at 590 nm was measured. For the determination of IC50 values, a dilution series of 
the extracts were tested following the same procedure as described before. IC50 values were calculated 
by using Excel to determine the concentration that shows a 50% inhibition of the viability. 
Supplementary Materials: The following are available online at https://www.mdpi.com/1660-3397/18/2/107/s1, 
HR-ESIMS and NMR spectra of compounds 1–3.  
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